ELMWOOD PARK, N.J. — Glenmark Pharmaceuticals has received approval from the U.S. Food and Drug Administration for fluticasone propionate nasal spray USP, 0.05 mg (50 mcg)/spray, a generic version of Haleon’s Flonase Nasal Spray.
Fluticasone propionate is a corticosteroid used to treat nasal allergy symptoms, including congestion, sneezing, and a runny nose.
“The approval of fluticasone propionate nasal spray USP, 0.05 mg/spray marks another step in expanding our respiratory portfolio in the United States and builds on the strong foundation we have established in this therapeutic area. We remain committed to broadening access to quality, affordable treatment options that address the evolving needs of patients and healthcare providers,” said Marc Kikuchi, president and business head, North America.
According to IQVIA data cited by Glenmark, Flonase Nasal Spray had a market value of approximately $295.2 million for the 12 months ended June 2026.
Glenmark Pharmaceuticals Inc., USA will distribute the product in the United States.
Submit Your Press Release
Have news to share? Send us your press releases and announcements.
Send Press Release
